Similar articles

• [Lipid lowering therapy in the treatment and secondary prevention of ischemic heart disease].

  Zimin IuV. Zimin IuV. Kardiologiia. 2003;43(4):74-83. Kardiologiia. 2003. PMID: 12968608 Review. Russian. No abstract available.
• [Efficacy of beta-selective blocker with vasodilatating features celiprolol in patients with mild and moderate hypertension].

  Pogosova GV, Zhidko NI, Mikheeva TG, Gudkova OA, Tikhomirova EA. Pogosova GV, et al. Kardiologiia. 2003;43(3):24-7. Kardiologiia. 2003. PMID: 12913979 Russian. No abstract available.
• Effect of celiprolol and metoprolol on lipids, fibrinogen and airways function in hyperlipidaemic hypertensives: a randomised double-blind long-term parallel group trial.

  Johnston GD, Vyssoulis G, Feely J, Holden RD, Radley DR. Johnston GD, et al. J Hum Hypertens. 1995 Feb;9(2):123-9. J Hum Hypertens. 1995. PMID: 7752174 Clinical Trial.
• [Adrenergic mechanisms and their significance for plasma lipid concentrations].

  Day JL. Day JL. Wien Med Wochenschr. 1982;132 Spec No 2:19-22. Wien Med Wochenschr. 1982. PMID: 6132497 Clinical Trial. German. No abstract available.
• Clinical and hemodynamic effects of celiprolol in essential hypertension.

  Parati G, Ravogli A, Bragato R, Omboni S, Mutti E, Mancia G. Parati G, et al. J Cardiovasc Pharmacol. 1989;14 Suppl 7:S14-21. J Cardiovasc Pharmacol. 1989. PMID: 2481785 Review.